Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
With
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Age
4–11
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Male or female children with a documented diagnosis of mild-to-moderate persistent asthma (according to the 2007 NIH \[EPR\] criteria) for at least 1 year prior to screening and medically stable for a minimum of 6 months prior to screening.
2. Children 4 through 11 years old (up to one day prior to their 12th birthday at randomization).
3. Body weight \>=45 lbs, body mass index (BMI) \<=30 kg/m2
4. ICS users had to have been taking an ICS for \>=3 months and on a stable dose for \>= 1 month before Visit 1.ICS users had to be stable enough and able to withhold their therapeutic ICS for 24 hours prior to study drug administration,
5. Subjects already on stable immunotherapy (ie, allergy shots)if not anticipated to change during the study.
You may not be if
1. Females of child-bearing potential/menarche.
2. Diagnosis of any other significant chronic illness or abnormality.
3. Use of corticosteroids
Clareo Health | Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma
